Isatuximab

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

ICARIA-MM: isatuximab, pomalidomide & dexamethasone

Immunomodulation for improving long-term outcomes in myeloma

Michel Delforge

IKEMA: kD vs isatuximab and kD in R/R myeloma

Philippe Moreau

The role of isatuximab in the management of MM

Management of R/R myeloma and MRD assessment

Short-duration fixed-volume infusion of isatuximab in relapsed/refractory myeloma

Isatuximab + VRd or VCd in newly diagnosed transplant-ineligible myeloma

Treatment strategies for high-risk MM

Jesús San Miguel

Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T

MRD as a tool to discontinue therapy in MM?

Key game-changers in multiple myeloma

Kenneth Anderson

Amyloidosis: diagnosis and stem cell transplantation

Morie Gertz et al.

How will novel agents affect the amyloidosis population?

Morie Gertz et al.

Attacking plasma cell dyscrasia in AL amyloidosis

Vaishali Sanchorawala

Highlights from IMW 2019 Part I

Francesca Gay et al.

1
2
3
Next